Kodiak Sciences (NASDAQ:KOD) PT Raised to $3.00

Kodiak Sciences (NASDAQ:KODGet Free Report) had its price target upped by research analysts at Barclays from $2.00 to $3.00 in a research report issued on Monday, Benzinga reports. The firm presently has an “underweight” rating on the stock. Barclays‘s price objective points to a potential downside of 30.72% from the company’s previous close.

KOD has been the subject of a number of other reports. UBS Group decreased their price objective on Kodiak Sciences from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Thursday, December 21st. The Goldman Sachs Group reissued a “sell” rating and issued a $2.00 price target on shares of Kodiak Sciences in a report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Kodiak Sciences has a consensus rating of “Hold” and a consensus price target of $6.00.

Check Out Our Latest Stock Report on Kodiak Sciences

Kodiak Sciences Stock Down 2.7 %

NASDAQ:KOD opened at $4.33 on Monday. The stock’s 50 day moving average price is $5.41 and its 200 day moving average price is $3.45. The company has a market capitalization of $227.20 million, a PE ratio of -0.87 and a beta of 2.15. Kodiak Sciences has a 52-week low of $1.37 and a 52-week high of $9.80.

Hedge Funds Weigh In On Kodiak Sciences

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Kodiak Sciences by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,643,470 shares of the company’s stock worth $4,996,000 after acquiring an additional 10,454 shares during the last quarter. Barclays PLC boosted its position in shares of Kodiak Sciences by 61.3% in the fourth quarter. Barclays PLC now owns 102,261 shares of the company’s stock worth $310,000 after buying an additional 38,877 shares during the period. Voya Investment Management LLC purchased a new stake in shares of Kodiak Sciences in the fourth quarter worth about $49,000. Newtyn Management LLC boosted its position in shares of Kodiak Sciences by 10.1% in the fourth quarter. Newtyn Management LLC now owns 1,771,241 shares of the company’s stock worth $5,385,000 after buying an additional 162,547 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in Kodiak Sciences by 2.7% in the fourth quarter. Nuveen Asset Management LLC now owns 145,449 shares of the company’s stock valued at $442,000 after purchasing an additional 3,769 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Kodiak Sciences

(Get Free Report)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

See Also

Analyst Recommendations for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.